Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. New issue in AttgeNO
Mandate

New issue in AttgeNO

May 02, 2018 M&A

The Swedish pharmaceutical research company AttgeNO has performed a new issue of shares.

AttgeNO works on the development of new pharmaceuticals which expand blood vessels. Supernitro (PDNO) is a new, patented pharmaceutical candidate for treatment of acute and life-threatening high blood pressure in the lungs, which, can arise for example in connection with heart surgery and may result in death. The capital generated as a result of the new issue of shares is intended to give AttgeNO an opportunity to perform clinical Phase 1 studies during 2019.

AttgeNO was advised by partner Johan Winnerblad.

Related

Vinge advises InArea on entering into a SEK 450 million credit agreement with SEB

 InArea's new facilities agreement comprises a term loan and a revolving credit facility, replacing the company's existing facilities. The facilities agreement also includes an option to increase the lending framework through an incremental facility of up to SEK 200 million.
June 03, 2026

Vinge has advised the arrangers in connection with St1 Biokraft’s EUR 260 million financing

 Vinge has advised the arrangers, ING Bank N.V., ABN AMRO Bank N.V., DNB Bank ASA, Nordea Bank Abp, OP Corporate Bank plc, Coöperatieve Rabobank U.A., SpareBank 1 Sør-Norge ASA and Swedbank AB, in connection with St1 Biokraft AB’s EUR 260 million financing.
June 03, 2026

Vinge advises Trinax Group in conjunction with the acquisition of AddMobile and Scudo Solutions

 Trinax Group has acquired the Swedish company AddMobile and the Finnish company Scudo Solutions, which specialise in software for work order management and project and cost management respectively. The two acquisitions broaden the group’s offering across the entire value chain, from the client’s budget and costing to the contractor’s field work, whilst strengthening its geographical presence in Finland.
June 03, 2026